NUP98 is fused to topoisomerase (DNA) IIβ 180 kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15)

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6489-6494

  Nebral, Karin ^a   Schmidt, Helmut H ^b   Haas, Oskar A ^a   Strehl, Sabine ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; COMPLEMENTARY DNA; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING) B; MITOXANTRONE; NUCLEOPORIN 98; PROTEIN TOP2B; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 3; COMPUTER ANALYSIS; CYTOGENETICS; DNA REPAIR; ENZYME ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REPLICATION; GENETIC RECOMBINATION; GENETIC SELECTION; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MALIGNANT TRANSFORMATION; MITOSIS; MOLECULAR CLONING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; STOP CODON; TRANSCRIPTION REGULATION;

ACUTE DISEASE; AMINO ACID SEQUENCE; BASE SEQUENCE; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 3; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NUCLEAR PORE COMPLEX PROTEINS; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SEQUENCE HOMOLOGY, NUCLEIC ACID; TRANSLOCATION, GENETIC;

EID: 25144500020     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0150     Document Type: Article

References (44)

1. Slape C, Aplan PD. The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma 2004;45:1341-50.
2. Kobzev YN, Martinez-Climent J, Lee S, Chen J, Rowley JD. Analysis of translocations that involve the NUP98 gene in patients with 11p15 chromosomal rearrangements. Genes Chromosomes Cancer 2004;41:339-52.
3. Powers MA, Forbes DJ, Dahlberg JE, Lund E. The vertebrate GLFG nucleoporin, Nup98, is an essential component of multiple RNA export pathways. J Cell Biol 1997;136:241-50.
4. Griffis ER, Xu S, Powers MA. Nup98 localizes to both nuclear and cytoplasmic sides of the nuclear pore and binds to two distinct nucleoporin subcomplexes. Mol Biol Cell 2003;14:600-10.
5. Griffis ER, Allan N, Lippincott-Schwartz J, Powers MA. Nup98 is a mobile nucleoporin with transcription-dependent dynamics. Mol Biol Cell 2002;13:1282-97.
6. Model AE, Model MR, Griffis ER, et al. The three-dimensional structure of the autoproteolytic, nuclear pore-targeting domain of the human nucleoporin Nup98. Mol Cell 2002;10:347-58.
7. Gervais C, Mauvieux L, Perrusson N, et al. A new translocation t(9;11)(q34;p15) fuses NUP98 to a novel homeobox partner gene, PRRX2, in a therapy-related acute myeloid leukemia. Leukemia 2005;19:145-8.
8. Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deursen JM. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol Cell Biol 1999;19:764-76.
9. Gurevich RM, Aplan PD, Humphries RK. NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation. Blood 2004;104:1127-36.
10. Arai Y, Kyo T, Miwa H, et al. Heterogenous fusion transcripts involving the NUP98 gene and HOXD13 gene activation in a case of acute myeloid leukemia with the t(2;11)(q31;p15) translocation. Leukemia 2000;14:1621-9.
11. Ghannam G, Takeda A, Camarata T, Moore MA, Viale A, Yaseen NR. The oncogene Nup98-HOXA9 induces gene transcription in myeloid cells. J Biol Chem 2004;279:866-75.
12. Mitelman F, editor. ISCN (1995): an international system for human cytogenetic nomenclature. Basel: S. Karger: 1995.
13. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 1998;58:4269-73.
14. Konig M, Reichel M, Marschalek R, Haas OA, Strehl S. A highly specific and sensitive fluorescence in situ hybridization assay for the detection of t(4:11)(q21:q23) and concurrent submicroscopic deletions in acute leukaemias. Br J Haematol 2002;116:758-64.
15. Nebral K, Konig M, Schmidt H, et al. Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization (FISH). Haematologica 2005;90:746-52.
16. Ahuja HG, Felix CA, Apian PD. The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood 1999;94:3258-61.
17. Reichel M, Gillert E, Nilson I, et al. Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 1998;17:3035-44.
18. Gillert E, Leis T, Repp R, et al. A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. Oncogene 1999;18:4663-71.
19. Iwase S, Akiyama N, Sekikawa T, et al. Both NUP98/ TOP1 and TOP1/NUP98 transcripts are detected in a de novo AML with t(11;20) (p15;q11). Genes Chromosomes Cancer 2003;38:102-5.
20. Ahuja HG, Felix CA, Aplan PD. Potential role for DNA topoisomerase II poisons in the generation of t(11;20)(p15;q11) translocations. Genes Chromosomes Cancer 2000;29:96-105.
21. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
22. Berger JM, Wang JC. Recent developments in DNA topoisomerase II structure and mechanism. Curr Opin Struct Biol 1996;6:84-90.
23. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996;379:225-32.
24. Berger JM. Type II DNA topoisomerases. Curr Opin Struct Biol 1998;8:26-32.
25. Sng JH, Heaton VJ, Bell M, Maini P, Austin CA, Fisher LM. Molecular cloning and characterization of the human topoisomerase IIα and IIβ genes: evidence for isoform evolution through gene duplication. Biochim Biophys Acta 1999;1444:395-406.
26. Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A 1988;85:7177-81.
27. Jenkins JR, Ayton P, Jones T, et al. Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res 1992;20:5587-92.
28. Bauman ME, Holden JA, Brown KA, Harker WG, Perkins SL. Differential immunohistochemical staining for DNA topoisomerase II α and β in human tissues and for DNA topoisomerase II β in non-Hodgkin's lymphomas. Mod Pathol 1997;10:168-75.
29. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998;1400:121-37.
30. St Pierre J, Wright DJ, Rowe TC, Wright SJ. DNA topoisomerase II distribution in mouse preimplantation embryos. Mol Reprod Dev 2002;61:335-46.
31. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 1997;75:1340-6.
32. Zandvliet DW, Hanby AM, Austin CA, et al. Analysis of foetal expression sites of human type II DNA topoisomerase α and β mRNAs by in situ hybridisation. Biochim Biophys Acta 1996;1307:239-47.
33. Christensen MO, Larsen MK, Barthelmes HU, et al. Dynamics of human DNA topoisomerases IIα and IIβ in living cells. J Cell Biol 2002;157:31-44.
34. Dingemans AM, Pinedo HM, Giaccone G. Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:275-88.
35. Wang JC. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q Rev Biophys 1998;31:107-44.
36. Mirski SE, Gerlach JH, Cole SP. Sequence determinants of nuclear localization in the α and β isoforms of human topoisomerase II. Exp Cell Res 1999;251:329-39.
37. Mirski SE, Bielawski JC, Cole SP. Identification of functional nuclear export sequences in human topoisomerase IIα and β. Biochem Biophys Res Commun 2003;306:905-11.
38. Nakamura T, Yamazaki Y, Hatano Y, Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood 1999;94:741-7.
39. Lupas A, Van Dyke M, Stock J. Predicting coiled coils from protein sequences. Science 1991;252:1162-4.
40. Hussey DJ, Dobrovic A. Recurrent coiled-coil motifs in NUP98 fusion partners provide a clue to leukemogenesis. Blood 2002;99:1097-8.
41. Wolf E, Kim PS, Berger B. MultiCoil: a program for predicting two- and three-stranded coiled coils. Protein Sci 1997;6:1179-89.
42. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
43. Wu X, Kasper LH, Mantcheva RT, Mantchev GT, Springett MJ, van Deursen JM. Disruption of the FG nucleoporin NUP98 causes selective changes in nuclear pore complex stoichiometry and function. Proc Natl Acad Sci U S A 2001;98:3191-6.
44. Saito S, Miyaji-Yamaguchi M, Nagata K. Aberrant intracellular localization of SET-CAN fusion protein, associated with a leukemia, disorganizes nuclear export. Int J Cancer 2004;111:501-7.